摘要
目的:比较米氮平与舍曲林治疗不同症状抑郁症的疗效。方法:将112例抑郁症诊断标准的患者,按不同主诉(精神症状或躯体症状)分为精神症状组56例和躯体症状组56例,每组患者再各随机分为米氮平组和舍曲林组(28例/28例),分别给予患者米氮平和舍曲林治疗6周。用汉密尔顿抑郁量表17项(HAMD)评定疗效,用治疗中出现的症状量表(TESS)评定不良反应。结果:精神症状中,米氮平组与舍曲林组患者疗效比较差异无显著性(P>0.05);躯体症状为主的患者中的米氮平组显效率(71.43%)高于舍曲林组(50.00%),两组患者比较差异有显著性(P<0.05)。结论:米氮平和舍曲林治疗以精神症状或躯体症状为主诉的抑郁症均有效,其中米氮平治疗躯体症状为主诉的抑郁症疗效更好。
Objective：To compare efficacy of Mirtazapine and Sertraline in treatment of depression with different symptoms.Methods：112 patients meeting with ICD-10 for depression were divided into psychotic symptom group（n = 56） and somatic symptom group（n = 56）,according to their different complaints.Then psychotic symptom group and somatic symptom group were randomly divided into two sub-groups respectively,Mirtazapine sub-group（n = 28/28） and Sertraline sub-group（n = 28/28）.They were treated for 6 weeks.The efficacy and adverse reactions were assessed by Hamilton depression scale（HAMD） and the treatment emergent symptom scale（TESS）,respectively.Results：There was no significant difference in the efficacy between Mirtazapine sub-group and Sertraline sub-group in the treatment of depressed patients with psychotic symptoms（P 0.05）.The response rate was significantly higher in patients of Mirtazapine sub-group compared with that in Sertraline sub-group（71.43% vs 50.00 %） in the treatment of depressed patients with somatic symptoms（P 0.05）.Conclusions：Mirtazapine and Sertraline are effective in the treatment of depression,and Mirtazapine responses earlier and is more effective in the treatment of depression with somatic symptoms.
出处
《中国民康医学》
2014年第10期28-29,共2页
Medical Journal of Chinese People’s Health
关键词
抑郁症
米氮平
舍曲林
Depression
Mirtazapine
Sertraline
